Fentanyl-Rewired: A 2-Azaspiro[3.3]heptane Core Preserves μ-Opioid Function

Click to copy article linkArticle link copied!

Opioid analgesics remain essential for severe pain, (1) yet their use is constrained by dose-limiting adverse effects and a public-health crisis driven by potent synthetics. (2) Fentanyl is an exceptionally efficacious MOR agonist that produces rapid, profound analgesia, (2) but also carries a well-documented risk of life-threatening respiratory depression (3) and has been a major driver of opioid overdose mortality when used nonmedically or encountered as illicitly manufactured fentanyl in the drug supply. (4) These pressures sharpen a central goal in opioid structure activity studies: preserve MOR-mediated analgesia while reshaping pharmacology to reduce risk.

One route to examine the phenylpiperidine class of synthetic opioid pharmacology is through scaffold hopping within the fentanyl chemotype to survey which elements encode its biological signature. Piperidine is the canonical core of fentanyl and a privileged motif across many drugs. (5) Compact spirocyclic amines─especially azaspiro[3.3]heptanes─have emerged as practical piperidine bioisosteres that maintain amine basicity and relative orientation of substituents while adding conformational restraint and three-dimensional shape. (6,7) Across matched pairs, azaspiro[3.3]heptanes typically lower lipophilicity, (8) increase intrinsic solubility, (7) and often reduce microsomal clearance versus six-membered monocyclic analogues (7)─advantages that have translated to comparable activity with improved metabolic stability in other series. (7)

Prior ring edits to the 4-anilidopiperidine scaffold─either conformationally restricting it to tropane frameworks or expanding it to perhydroazepines─showed potency to be highly stereochemistry-dependent, with several analogues losing efficacy or retaining morphine-like liability profiles. (9,10) Because these approaches primarily probed ring contraction/expansion within the 4-anilidopiperidine framework without clearly uncoupling analgesia from morphine-like dependence, we replaced the piperidine with a compact 2-azaspiro[3.3]heptane bioisostere within the fentanyl chemotype, preserving key vectors while introducing a compact 3D constraint and new physicochemical/pharmacokinetic tuning potential to test whether μ-opioid pharmacology can be retained yet signaling and disposition shifted.

In parallel, attempts to dissociate analgesia from respiratory depression have focused on MOR signaling, (11) particularly the balance between G-protein and β-arrestin-2 pathways. (12) Fentanyl engages both pathways at MOR. (13) By contrast, weak β-arrestin-2-recruiting ligands display distinct in vivo effects, (14,15) implying that the relative engagement of G-protein versus β-arrestin-2 pathways modulates the overall phenotype. (14,16) While the clinical generality remains debated, (17,18) deliberately tuning MOR signaling remains a compelling strategy for next-generation opioids.

Based upon this agenda, we probed portability by swapping the piperidine for 2-azaspiro[3.3]heptane while preserving phenethyl and anilide orientations (Figure 1). Across orthogonal assays─MOR/DOR/KOR binding, β-arrestin-2 readout, mouse-serum stability, pharmacokinetics, antinociception, acute tolerability, and whole-body plethysmography─the spiro core preserved a fentanyl-like profile yet shifted potency, exposure, and β-arrestin recruitment. The outcome establishes a practical template: spiro substitution can retain class-defining μ-opioid pharmacology while opening tractable levers in signaling and disposition to engineer wider therapeutic indices.

Figure 1

High Resolution Image

Download MS PowerPoint Slide

To enable evaluation, we developed a concise four-step synthesis of analogue 1 from commercial tert-butyl 6-oxo 2-azaspiro[3.3]heptane-2-carboxylate (Scheme 1). Synthesis started with the reductive amination of the C-6 ketone with aniline and NaBH(OAc)₃, giving secondary amine 3 quantitatively, while the Boc group was retained to dampen basicity on the N(spiro) ring as well as suppress side reactions during the condensation/reduction. With 3 secure, acylation of the aniline with propionyl chloride furnished propionanilide 4 in 56% yield. It should be mentioned that Boc protection upon the N(spiro) functionality prevented competing acylation and ensured anilide selectivity. Boc deprotection with TFA was then employed to unmask the ring’s secondary amine, affording 5. Finally, N-alkylation with 2-phenethyl iodide afforded N-phenethyl tertiary amine 1 in 73% yield over two steps. It is worth noting that the iodide electrophile consistently outperformed the bromide in this SN2 step, giving higher conversion and fewer byproducts, which simplified purification. Finally, it should be understood that this route mirrors canonical fentanyl syntheses (19) from 4-piperidone while enabling the spirocyclic replacement of piperidine.

Scheme 1

High Resolution Image

Download MS PowerPoint Slide

To translate the chemical design into pharmacology, in vitro binding studies for 1 were performed off-site under a standardized protocol. The binding affinity of 1 for the opioid receptors was evaluated by using competitive radioligand displacement assays in a two-stage workflow. In the primary screen, 1 was tested at a concentration of 10 μM resulting in%-inhibition of 78.79 ± 2.14% at MOR, 65.94 ± 5.41% at KOR, and 28.60 ± 5.10% at DOR, thus exhibiting the rank order MOR > KOR ≫ DOR. Owing to the low DOR signal (<50% inhibition), secondary radioligand binding assays focused on MOR and KOR using [³H]DAMGO and [³H]U69593, respectively (Figure 2). Full concentration curves of 1 were generated across two independent assays per target receptor resulting in binding affinities of K_i = 1.17–1.68 μM (geometric mean 1.40 μM, pK_i ≈ 5.85) at MOR and K_i = 3.70–5.03 μM (geometric mean 4.32 μM, pK_i ≈ 5.36) at KOR, corresponding to ∼3-fold selectivity for MOR over KOR.

Figure 2

High Resolution Image

Download MS PowerPoint Slide

The β-arrestin activity of 1 was assessed using a β-arrestin-2 recruitment assay in comparison to the reference MOR agonist DAMGO (Figure S1). While DAMGO produced a robust β-arrestin-2 recruitment response, 1 produced no detectable signal over the concentration range tested (up to ∼30 μM), indicating no measurable β-arrestin-2 recruitment under these conditions and implying that any β-arrestin-2 engagement, if present, lies below the assay’s detection threshold.

With serum degradation unlikely to limit exposure, we next characterized the in vivo disposition of 1. Analysis of the plasma concentration–time profile (Figure 3) shows rapid systemic exposure following administration of a intravenous (IV) bolus dose of 150 μg/kg, with a subsequent monoexponential decline. Noncompartmental modeling afforded an elimination half-life of approximately 27 min, a clearance of 13.3 mL·min^–1·kg^–1 and a volume of distribution of 0.52 L·kg^–1. Extrapolation to time zero gave C₀ ≈ 6.7 μM, and the area under the curve was AUC₀–∞ ≈ 10 μM·min. Together, these observations are characteristic of a short-acting profile with low-moderate clearance and modest distribution

Figure 3

High Resolution Image

Download MS PowerPoint Slide

For context, previous acute mouse biodistribution studies comparing respiratory-depressant-relevant doses of fentanyl and morphine reported that fentanyl (0.3 mg/kg sc) reaches maximal concentrations in key tissues on a rapid time scale, with t_max ∼ 15 min in whole blood, brain, liver, and lung, and exhibits greater early redistribution from blood into brain, liver, lung, and heart than morphine. (20) Against this benchmark, the IV pharmacokinetics of 1─with rapid exposure evident by the earliest sampling point (5 min) and a short elimination half-life (∼27 min)─is consistent with an acute, short-acting profile appropriate for fentanyl-class comparison.

To evaluate potential toxicity, mice (n = 4 per dose) received increasing amounts of 1 (IV) and were monitored continuously for adverse effects and mortality. At 10 mg kg^–1, mice appeared normal with no indication of distress or signs of acute toxicity except for slight piloerection. At 30 mg kg^–1, mild and brief seizure activity was observed in all animals along with immediate and prominent piloerection. At 50 mg kg^–1, generalized clonic-tonic seizures occurred rapidly and persisted in all mice; 2 of 4 mice died within 5–10 min at this dose. These data establish a dose-dependent neurotoxic threshold under acute IV bolus conditions and delineate a practical upper bound for subsequent efficacy studies.

MOR activation triggers intracellular signaling pathways thought to be associated with analgesia and respiratory depression, respectively. (11) To determine whether the spiro substitution preserves system-level analgesia, we evaluated 1 alongside fentanyl (reference control) in both hot plate and tail flick antinociception assays, which are often used to measure supraspinally and spinally mediated analgesic potencies of opioid-like drugs in rodents. In these assays, animals are cumulatively dosed with drug (IP) and their response to thermal stimuli measured until 100% maximal potential effect (MPE) is reached. Effective dose 50 (ED₅₀) values calculated from the dose–response curves enables quantitative comparison of drug analgesic potencies. As anticipated, fentanyl produced strong analgesic effects in the μg/kg range, with ED₅₀ values of 82 and 87 μg/kg for hot plate and tail flick tests, respectively (Figure 4). In contrast, a mg/kg dosing range of 1 was required to produce a measurable effect resulting in hot plate and tail flick ED₅₀ values of 9 and 14 mg/kg. These ED₅₀ values correspond to ∼115-fold (hot plate) and ∼165-fold (tail flick) lower potency for 1, yet full antinociceptive efficacy was still achieved. Notably, during dosing of 1, piloerection was observed at all concentrations and became more pronounced with increasing doses. However, the straub tail effect, a classic opioid-induced response caused by CNS activation, was only noticeable in fentanyl-dosed mice and not observed in mice dosed with 1.

Figure 4

High Resolution Image

Download MS PowerPoint Slide

Drug-induced respiratory depression is a serious and often fatal side effect of opioid medications caused by activation of MOR. (21,22) Thus, whole-body plethysmography was used to measure the potential respiratory depressive effects of 1 (Figure 5). Mice dosed with 1 (IP) generally showed a dose-dependent decrease in minute volume (MV) between 5 and 40 mg/kg with maximal respiratory depression observed within ∼10 min, consistent with other opioids. (23) However, MV returned to baseline within 25 min post-injection of all doses.

Figure 5

High Resolution Image

Download MS PowerPoint Slide

Thus, 1 produces a rapid but transient ventilatory liability typical of opioids, normalizing by ∼25–30 min. Framed by this profile, we asked how far the fentanyl pharmacophore can be altered while preserving MOR preference and robust antinociception while retuning signaling and disposition. To probe this query, we replaced the central piperidine to a 2-azaspiro[3.3]heptane, with phenethyl/anilide geometry preserved, which delivered a recognizably fentanyl-class phenotype (MOR-preferred binding; full analgesic efficacy) but diverged from fentanyl in pathway engagement, showing abolished β-arrestin-2 recruitment activity despite fentanyl’s known engagement of this pathway. (24)

Receptor pharmacology quantified the portability of such a bioisosteric replacement approach. Thus, in primary affinity analysis the analogue favored MOR over KOR ≫ DOR, and secondary determinations placed MOR affinity in the low micromolar range (K_i ≈ 1.17–1.68 μM) with weaker KOR binding (K_i ≈ 3.70–5.03 μM). Although absolute potency is markedly reduced versus the typical low-nanomolar MOR K_i of fentanyl, the selectivity pattern is preserved using the spiro core, providing a clear baseline for structure–activity efforts to recover affinity while maintaining target preference.

Moreover, pharmacokinetics indicated a short-acting compound with moderate clearance and a modest volume of distribution. After an IV bolus dose, plasma concentrations declined monoexponentially; a parameter set that does not suggest extensive tissue retention. The molecule was stable in mouse serum for more than 24 h, indicating that the brief exposure reflects its pharmacokinetic properties rather than rapid degradation.

Assessing acute toxicity via bolus IV injections, we observed liabilities only at higher exposures. At 10 mg kg^–1, animals displayed piloerection without seizure activity. At 30 mg kg^–1, brief seizure activity occurred without mortality; at 50 mg kg^–1, seizures were universal with 50% lethality within ∼5–10 min. During antinociception testing, seizure activity was noted in one mouse at a cumulative IP dose of 60 mg kg^–1. However, these adverse effects arose at drug doses well above those producing maximal antinociceptive effects, indicating that significant efficacy is attainable below the threshold for neurobehavioral toxicity. These findings motivate exposure–response studies (brain/plasma C_max and rate-of-rise), evaluation of route/formulation influences, receptor-level antagonism, and EEG/telemetry, as well as SAR around the spiro amine and anilide/phenethyl regions, to further separate efficacy from high-dose liabilities.

To contextualize the in vitro pharmacology, we docked fentanyl and 1 into the MOR. In our model, 1 adopts a pose that preserves the canonical ionic/hydrogen-bonding anchor to Asp^3.32 (Asp149 in our system) and additionally engages His^6.52 (His299) (25) via π–π stacking (Figure 6). By comparison, fentanyl retains the Asp^3.32 interaction and exhibits a more extensive secondary stabilization network within the aromatic pocket, including H-bonding to Tyr^3.33 (Tyr150) (26) and π–π/edge-to-face contacts with Trp^6.48 (Trp295), Tyr^7.43 (Tyr328), and Trp^2.63 (Trp135) (Figure 6). Thus, relative to fentanyl, (25,27) the spiro analogue appears to attenuate aromatic cage engagement beyond the primary Asp^3.32 anchor, with fewer cooperative contacts spanning TM2/3/6/7, consistent with a qualitatively shallower aromatic packing environment. In line with this interaction profile, fentanyl scored more favorably than 1 (docking scores: fentanyl – 7.445 vs 1 – 5.674; more negative indicates stronger predicted affinity). We note that docking provides a static, receptor-state-dependent snapshot; thus, while these interactions are consistent with known MOR pharmacophore elements (D3.32 salt bridge/H-bond and a multiresidue aromatic cage across TM2/3/6/7), they should be interpreted cautiously with respect to efficacy or bias. Complementing the binding-site interaction modeling, docking renderings of the MOR orthosteric site show the poses of bioisostere 1, fentanyl, and their overlay to illustrate conserved D3.32 anchoring and the reduced/shifted aromatic engagement of 1 relative to fentanyl (Figure 7).

Figure 6

High Resolution Image

Download MS PowerPoint Slide

Figure 7

High Resolution Image

Download MS PowerPoint Slide

In summary, these results reframe what is possible for the fentanyl chemotype. A wholesale piperidine→2-azaspiro[3.3]heptane swap preserves a recognizably fentanyl-like phenotype─maintained MOR preference, full antinociception, and a transient, frequency-driven ventilatory effect─while decisively shifting both potency and exposure. Crucially, the analogue also separates from fentanyl along two liability-relevant axes: no apparent β-arrestin-2 engagement (fentanyl recruits this pathway (24)) and respiratory depression that emerges only at mg/kg doses and appears short-lived, rather than the μg/kg range typical for fentanyl. (28) Put simply, this is not just pharmacophore portability; it is a usable design lever.

The spiro core offers a concrete way to disentangle efficacy from features that often track with risk. It retains the essential Asp^3.32 anchoring logic of the fentanyl scaffold, yet opens multiple, experimentally tractable knobs for optimization. First, anilide electronics can potentially be tuned with simple para-substitution (e.g., p-F, p-Cl, p-CF₃, p-OMe) to rebalance aromatic-pocket stabilization without disrupting the conserved ionic/H-bonding anchor. Second, the phenethyl vector provides a high-yield opportunity to shape conformational preference and deepen engagement with the MOR aromatic cage; α-methyl or 3-methyl substitutions are obvious, fentanyl-validated moves to test in this new topological context. Third, the basicity and residence of the 2-azaspiro[3.3]heptane nitrogen can be systematically modulated via proximal electron-withdrawing substitution (e.g., α-fluoro or gem-difluoro patterns on the spiro framework), offering a clean way to interrogate potency–bias relationships while keeping the scaffold hop intact.

Taken together, this blueprint suggests a disciplined path forward: preserve the “fentanyl signature” at MOR, deliberately reprogram signaling and exposure through the spiro topology, and then recover affinity by iterating these specific SAR levers under exposure-matched functional readouts─including respiratory time course. The broader implication is simple and powerful: topological remodeling can convert a historically rigid chemotype into a modular platform for separating desirable opioid efficacy from key mechanistic liabilities.